Susquehanna International Group, LLP Taysha Gene Therapies, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.01 - $2.46 $68,340 - $83,640	-34,000 Reduced 68.69%	15,500 $31,000
Q2 2024 Aug 15, 2024	BUY	$2.04 - $4.17 $44,880 - $91,740	22,000 Added 80.0%	49,500 $110,000
Q1 2024 May 07, 2024	SELL	$1.43 - $3.25 $10,868 - $24,700	-7,600 Reduced 21.65%	27,500 $78,000
Q4 2023 Feb 14, 2024	SELL	$1.33 - $2.88 $66,766 - $144,576	-50,200 Reduced 58.85%	35,100 $62,000
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $53,739 - $312,198	85,300 New	85,300 $269,000
Q3 2022 Nov 14, 2022	BUY	$1.76 - $4.94 $27,456 - $77,064	15,600 New	15,600 $30,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $97.2M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.